Sophocarpine monohydrate
Based on 12 publication(s) in Google Scholar
Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage.
For research use only. We do not sell to patients.
- Purity : 99.91%
- CAS No.: 145572-44-7
- Formula: C15H24N2O2
- Molecular Weight:264.36
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Sophocarpine monohydrate
More- Phytomedicine. 2025 Jul 25:143:156833. [Abstract]
- Phytomedicine. 2025 May:140:156484. [Abstract]
- Acta Pharmacol Sin. 2026 Jan 7. [Abstract]
- J Ethnopharmacol. 2022 Mar 1:285:114796. [Abstract]
- Eur J Pharmacol. 2023 Jul 5:950:175745. [Abstract]
- Int Immunopharmacol. 2026 May 1:176:116468. [Abstract]
- Molecules. 2022 Nov 15;27(22):7868. [Abstract]
- Mediators Inflamm. 2026 Feb 23:2026:5524066. [Abstract]
- Sci Rep. 2024 Jan 3;14(1):428. [Abstract]
- FASEB J. 2026 May 31;40(10):e71905. [Abstract]
- PeerJ. 2022 Sep 16;10:e14042. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
-
IF
-
WB
-
WB
All MEK Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
PI3K |
In Vitro
Sophocarpine monohydrate (0.5-4 mM; 24-48 h) inhibits cell viability, proliferation and migration, induces cell cycle G0/G1 arrest and apoptosis, upregulates PTEN and downregulates PI3K/Akt signaling pathways in glioblastoma cells (U251, C6)[1].
Sophocarpine monohydrate (0.4 mM; 24-72 h) inhibits cell proliferation and migration, downregulates MEK/ERK phosphorylation and VEGF-A/C/D secretion, and reduces N-cadherin and MMP-9 expression in colorectal cancer cells (HCT116, SW620)[2].
Sophocarpine monohydrate (50-100 μg/mL; 24 h) inhibits LPS-induced NO, TNF-α, and IL-6 production in RAW 264.7 macrophages, downregulates iNOS and COX-2 protein expression, and inhibits NF-κB activation and p38 and JNK phosphorylation in RAW 264.7 macrophages[3].
Sophocarpine monohydrate (1-5 μM; 24 h pretreatment + 12 h DOX cotreatment) reduces ROS levels in H9C2 cardiomyocytes, upregulates Nrf2/HO-1 signaling, inhibits DOX (HY-15142A)-induced Bax and cleaved-caspase-3 expression, and upregulates Bcl-2 in H9C2 cardiomyocytes[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:U251, C6 glioblastoma cells
-
Concentration:0.5, 1, 2, 4 mM
-
Incubation Time:24-48 h
-
Result:Reduced cell viability in a dose- and time-dependent manner, with IC50 around 2 mM at 48 hours, as measured by CCK-8 assay.
No significant cytotoxicity was observed in primary astrocytes at these concentrations.
-
Cell Line:U251 glioblastoma cells
-
Concentration:2 mM
-
Incubation Time:24 h
-
Result:Resulted a significant increase in subG1 phase cells (apoptotic cells) and G0/G1 phase arrest.
-
Cell Line:U251 glioblastoma cells[1] HCT116, SW620 colorectal cancer cells[2]
-
Concentration:2 mM for U251 cells; 0.4 mM for HCT116, SW620 cells
-
Incubation Time:24 h, 48 h
-
Result:Upregulation of cleaved Caspase-3, P53, and downregulation of Bcl-2, indicating induction of intrinsic apoptosis in U251 cells[1].
Downregulated phosphorylated MEK (p-MEK), phosphorylated ERK (p-ERK), N-cadherin, and MMP-9 in HCT116, SW620 cells, while VEGF-A/C/D secretion reduced[2].
In Vivo
Sophocarpine (10-30 mg/kg; intraperitoneal injection; twice a week; 4 weeks) monohydrate improves cardiac function, reduces CK, CK-MB, and LDH levels, and alleviates oxidative stress and cardiomyocyte apoptosis in a DOX (HY-15142A)-induced cardiac injury model in C57BL/6J mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c Nude Mouse Glioblastoma Xenograft Model (male, 18-24 g, 6-8 weeks old): subcutaneous and orthotopic U251 glioblastoma xenografts[1]
-
Dosage:35 mg/kg Sophocarpine
-
Administration:Intraperitoneal injection, every 2 days for 2 weeks (subcutaneous model); daily for 2 weeks (orthotopic model)
-
Result:Significantly reduced subcutaneous tumor volume and weight by 50% compared to control.
Echocardiography and histology showed no cardiotoxicity.
Western blot in tumor tissues revealed upregulated PTEN and cleaved Caspase-3, downregulated p-Akt and Bcl-2, indicating activation of the PTEN/PI3K/Akt pathway to induce apoptosis.
Immunohistochemistry confirmed reduced Ki-67 proliferation marker and increased PTEN expression.
-
Animal Model:C57BL/6J Mouse Doxorubicin-Induced Heart Injury Model (male, 25 g, 7 weeks old): Doxorubicin (5 mg/kg weekly×4 weeks) induced cardiotoxicity[4]
-
Dosage:10 mg/kg or 30 mg/kg Sophocarpine
-
Administration:Intraperitoneal injection, co-administered with Doxorubicin weekly for the last 2 weeks (after initial 2 weeks of doxorubicin alone), total 4 weeks
-
Result:Echocardiography showed improved left ventricular ejection fraction (LVEF) and fractional shortening (LVFS).
Serum biomarkers CK, CK-MB, and LDH were reduced by 30-40% compared to doxorubicin group.
DHE staining revealed decreased myocardial superoxide production, while MDA levels were lowered and SOD/GSH increased.
Western blot showed upregulated Nrf2/HO-1 signaling, reduced NOX-4 and pro-apoptotic proteins (Bax, cleaved-caspase-3, Cyto-C), and increased anti-apoptotic Bcl-2 in heart tissues.
Chemical Information
-
CAS No. 145572-44-7
-
Appearance Solid
-
Molecular Weight 264.36
-
Formula C15H24N2O2
-
Color Light yellow to yellow
-
SMILES
O=C1N(C[C@@]2([H])[C@@]3([H])[C@]4([H])CCCN3CCC2)[C@]4([H])CC=C1.O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Sophocarpine suppresses MAPK-mediated inflammation by restoring gut microbiota in colorectal cancer. [Abstract]2025 Jul 25:143:156833. PMID: 40393246 -
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
Acta Pharmacol Sin
Sophocarpine alleviates chronic itch in mouse atopic dermatitis by inhibiting spinal astrocyte reactivity and pro-inflammatory signaling. [Abstract]2026 Jan 7. PMID: 41501419 -
J Ethnopharmacol
Isoxanthohumol, a component of Sophora flavescens, promotes the activation of the NLRP3 inflammasome and induces idiosyncratic hepatotoxicity. [Abstract]2022 Mar 1:285:114796. PMID: 34740771 -
Eur J Pharmacol
2023 Jul 5:950:175745. PMID: 37146706
Sophocarpine monohydrate purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Jul 5:950:175745. [Abstract]
Sophocarpine (20 mg/kg; i.p.; daily; one week) significantly reduces the level of oxidative stress in mice.
Sophocarpine monohydrate purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Jul 5:950:175745. [Abstract]
Sophocarpine (20 mg/kg; i.p.; daily; one week) and LPS together significantly increases the expression of Nrf2 and HO-1 in mice.
-
Int Immunopharmacol
Minimolide F alleviates inflammatory diseases by specifically targeting STING and blocking IRF3 recruitment. [Abstract]2026 May 1:176:116468. PMID: 41819671 -
Molecules
Sophocarpine Alleviates Isoproterenol-Induced Kidney Injury by Suppressing Inflammation, Apoptosis, Oxidative Stress and Fibrosis. [Abstract]2022 Nov 15;27(22):7868. PMID: 36431969
Sophocarpine monohydrate purchased from MedChemExpress. Usage Cited in: Molecules. 2022 Nov 15;27(22):7868. [Abstract]
Sophocarpine (SOP; 20, 40 mg/kg; i.p.; once per day over two weeks) significantly hinders the ISO(Isoproterenol)-induced increase in TLR-4 and phosphorylation of NF-κB in mice.
-
Mediators Inflamm
Targeting Pulmonary Hypertension: Elucidating Sophocarpine's Protective Role via Preclinical Models. [Abstract]2026 Feb 23:2026:5524066. PMID: 41737847 -
Sci Rep
Sophocarpine alleviates doxorubicin-induced heart injury by suppressing oxidative stress and apoptosis. [Abstract]2024 Jan 3;14(1):428. PMID: 38172265 -
FASEB J
2026 May 31;40(10):e71905. PMID: 42149696 -
PeerJ
Sophocarpine inhibits tumor progression by antagonizing the PI3K/AKT/mTOR signaling pathway in castration-resistant prostate cancer. [Abstract]2022 Sep 16;10:e14042. PMID: 36132221 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (378.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
-
Handling Instructions (2659 KB)
References
[1]. Xing S, et al. Sophocarpine inhibits the progression of glioblastoma via PTEN/PI3K/Akt signaling pathway. Am J Cancer Res. 2024 Aug 25;14(8):3757-3772. [Content Brief]
[2]. Wang Q, et al. Sophocarpine Inhibits Tumorgenesis of Colorectal Cancer via Downregulation of MEK/ERK/VEGF Pathway. Biol Pharm Bull. 2019 Nov 1;42(11):1830-1838. [Content Brief]
[3]. Gao Y, et al. Anti-inflammatory effects of sophocarpine in LPS-induced RAW 264.7 cells via NF-κB and MAPKs signaling pathways. Toxicol In Vitro. 2012 Feb;26(1):1-6. [Content Brief]
[4]. Zhang HJ, et al. Sophocarpine alleviates doxorubicin-induced heart injury by suppressing oxidative stress and apoptosis. Sci Rep. 2024 Jan 3;14(1):428. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7827 mL | 18.9136 mL | 37.8272 mL | 94.5680 mL |
| 5 mM | 0.7565 mL | 3.7827 mL | 7.5654 mL | 18.9136 mL | |
| 10 mM | 0.3783 mL | 1.8914 mL | 3.7827 mL | 9.4568 mL | |
| 15 mM | 0.2522 mL | 1.2609 mL | 2.5218 mL | 6.3045 mL | |
| 20 mM | 0.1891 mL | 0.9457 mL | 1.8914 mL | 4.7284 mL | |
| 25 mM | 0.1513 mL | 0.7565 mL | 1.5131 mL | 3.7827 mL | |
| 30 mM | 0.1261 mL | 0.6305 mL | 1.2609 mL | 3.1523 mL | |
| 40 mM | 0.0946 mL | 0.4728 mL | 0.9457 mL | 2.3642 mL | |
| 50 mM | 0.0757 mL | 0.3783 mL | 0.7565 mL | 1.8914 mL | |
| 60 mM | 0.0630 mL | 0.3152 mL | 0.6305 mL | 1.5761 mL | |
| 80 mM | 0.0473 mL | 0.2364 mL | 0.4728 mL | 1.1821 mL | |
| 100 mM | 0.0378 mL | 0.1891 mL | 0.3783 mL | 0.9457 mL |